a study of 5-oxo-hexahydroquinoline derivatives
the Gromacs format using the ACPYPE python tool.47 The References
1. Chang A. Chemotherapy, chemoresistance and the changing treatment
landscape for NSCLC. Lung Cancer. 2011;71(1):3–10.
most favorite pose from the docking study was selected as
the starting structure for MD simulation.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role
of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
3. Juliano RL, Ling V. A surface glycoprotein modulating drug perme-
ability in Chinese hamster ovary cell mutants. Biochim Biophys Acta.
1976;455(1):152–162.
4. Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions
and structure of ABC transporters: implications for the design of new
inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
Curr Drug Targets. 2006;7(7):893–909.
5. Schneider E, Hunke S. ATP-binding-cassette (ABC) transport systems:
functional and structural aspects of the ATP-hydrolyzing subunits/
domains. FEMS Microbiol Rev. 1998;22(1):1–20.
6. Yuan H, Li X, Wu J, et al. Strategies to overcome or circumvent P-
glycoproteinmediatedmultidrugresistance. CurrMedChem. 2008;15(5):
470–476.
7. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein
reversal in solid tumours. Eur J Cancer. 1996;32A(6):1070–1081.
8. Lhommé C, Joly F, Walker JL, et al. Phase III study of valspodar (PSC
833) combined with paclitaxel and carboplatin compared with paclitaxel
and carboplatin alone in patients with stage IV or suboptimally debulked
stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin
Oncol. 2008;26(16):2674–2682.
9. Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-
label, parallel-cohort, dose-findingstudyofelacridar(GF120918)andoral
topotecan in cancer patients. Clin Cancer Res. 2007;13(11):3276–3285.
10. Robey RW, Shukla S, Finley EM, et al. Inhibition of P-glycoprotein
(ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-
mediated transport by the orally administered inhibitor, CBT-1®.
Biochem Pharmacol. 2008;75(6):1302–1312.
statistical analysis
The data, expressed as the mean ± SEM, were analyzed by
one-way ANOVA using the SPSS software version 14.0
for Windows. Differences with P,0.05 were considered
statistically significant.
Conclusion
Twenty-six novel 5-oxo-hexahydroquinoline derivatives pos-
sessing variable activities against MDR cell line MES-SA/
Dx5 were designed and synthesized. The MDR reversal
profile was evaluated using Rh123 as substrate and verapamil
as a reference drug. The most potent compounds were sub-
jected to further evaluation by measurement of MES-SA-Dx5
cells’ sensitivity to DXR by MTT assay. Compounds with
2-nitrophenyl moiety such as 2c, 5c and 6c showed good
activity profiles in both tests and proved to be the most inter-
esting molecules for further investigations. The effect of test
compounds against HEK293 cell line was investigated at 5,
10 and 25 µM, and no significant cytotoxicity was observed
except for compound 2c. In order to understand the structural
requirement of 5-oxo-hexahydroquinoline derivatives’ inter-
actions with P-gp, an MD simulation was performed, and the
binding interactions of compound 5c in a homology-modeled
human P-gp were investigated. The results indicated that
stabilization of 5c occurs through different hydrogen bonds
and also hydrophobic and arene–π interactions.
11. Ross DD. Modulation of drug resistance transporters as a strategy for
treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;
17(4):641–651.
12. Ruff P, Vorobiof DA, Jordaan JP, et al. A randomized, placebo-
controlled, double-blind phase 2 study of docetaxel compared to doc-
etaxel plus zosuquidar (LY335979) in women with metastatic or locally
recurrent breast cancer who have received one prior chemotherapy
regimen. Cancer Chemother Pharmacol. 2009;64(4):763–768.
13. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel block-
ers bind specifically to multidrug-resistant human KB carcinoma mem-
brane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem.
1987;262(5):2166–2170.
14. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL.
Identification of the multidrug resistance-related membrane glycopro-
tein as an acceptor for calcium channel blockers. J Biol Chem. 1987;
262(16):7884–7888.
15. Nogae I, Kohno K, Kikuchi J, et al. Analysis of structural features of
dihydropyridine analogs needed to reverse multidrug resistance and to
inhibit photoaffinity labeling of P-glycoprotein. Biochem Pharmacol.
1989;38(3):519–527.
16. Khoshneviszadeh M, Edraki N, Javidnia K, et al. Synthesis and biologi-
cal evaluation of some new 1,4-dihydropyridines containing different
ester substitute and diethyl carbamoyl group as anti-tubercular agents.
Bioorg Med Chem. 2009;17(4):1579–1586.
Abbreviations
3D, three-dimensional; ABC, ATP-binding cassette; DHPs,
dihydropyridines; DMSO, dimethyl sulfoxide; DXR,
doxorubicin; FBS, fetal bovine serum; IR, infrared; MD,
molecular dynamics; MDR, multidrug resistance; NMR,
nuclear magnetic resonance; P-gp, P-glycoprotein; PBS,
phosphate-buffered saline; Rh123, rhodamine 123; RPMI,
Rosewell Park Memorial Institute; SAR, structure–activity
relationship.
17. Razzaghi-Asl N, Firuzi O, Hemmateenejad B, Javidnia K, Edraki N,
Miri R. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl)
carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1
inhibitors. Bioorg Med Chem. 2013;21(22):6893–6909.
18. Fassihi A, Azadpour Z, Delbari N, et al. Synthesis and antitubercular
activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-
1,4-dihydropyridine-3,5-dicarboxamides. Eur J Med Chem. 2009;
44(8):3253–3258.
Acknowledgment
The authors thank the support of the Vice-Chancellor for
Research of Shiraz University of Medical Sciences (grant
number: 93-7237). This study was part of the PhD thesis of
Omolbanin Shahraki.
19. Sirisha K, Bikshapathi D, Achaiah G, Reddy VM. Synthesis, antibacte-
rial and antimycobacterial activities of some new 4-aryl/heteroaryl-2,6-
dimethyl-3,5-bis-N-(aryl)-carbamoyl-1,4-dihydropyridines. Eur J Med
Chem. 2011;46(5):1564–1571.
Disclosure
The authors report no conflicts of interest in this work.
Drug Design, Development andTherapy 2017:11
417